(3,3-dimethyl-2H-1-benzofuran-5-yl) cyclopropanecarboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: (3,3-dimethyl-2H-1-benzofuran-5-yl) cyclopropanecarboxylate
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.27
• InChiKey: PTKOORQQFDDAAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20140080826A1

  公开（公告）日：2014-03-20

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物可用作ATP结合盒（“ABC”）转运体或其片段的调节剂，包括囊性纤维化跨膜电导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运体介导的疾病的方法。
• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20140121208A1

  公开（公告）日：2014-05-01

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运体调节剂化合物（公式A、公式B、公式C或公式D）的制药组合物。本发明还涉及其制药配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化病的方法。
• Modulators of ATP-Binding Cassette Transporters
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20150094304A1

  公开（公告）日：2015-04-02

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可以接受的组合物，可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导疾病的方法。
• Modulators of ATP-binding cassette transporters
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10975061B2

  公开（公告）日：2021-04-13

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物可用作 ATP 结合盒（"ABC"）转运体或其片段（包括囊性纤维化跨膜传导调节器（"CFTR"））的调节剂。本发明还涉及使用本发明化合物治疗 ABC 转运体介导的疾病的方法。
• US8952050B2
  申请人：——

  公开号：US8952050B2

  公开（公告）日：2015-02-10